Prix Galien 2017 USA Forum convened in New York City, where key healthcare innovation leaders gathered to discuss trending health challenges. Organized by the Galien Foundation, with support from Finn Partners, the Forum and the Prix Galien combine the intensity of Davos with the excitement of the Nobel Prize for achievements that can change the human condition.
During the Forum keynote, top pharma executives discussed drug pricing and access through the lens of the Trump Administration. The exchange centered on how there is not a “one size fits all” approach to the pricing problem and how to chart a path forward. Panelists grappled with the challenge on how to measure success—patient care or business priorities. The pendulum now swings toward “how does a drug impact patient lives.”
The panelists touched on fair market versus fair profit. Executives acknowledged the need to shift the health ecosystem to operate under the indication-based reimbursement model, where the price of a drug correlates to how well it works.
The discussion concluded with panelists reiterating that there is not just one approach to the pricing conundrum—nor is one sector able to fix this alone. Patients, physicians, providers, payers, and policymakers must work together to find a solution.
While that was the big news coming out of the forum, the Prix Galien Awards Gala had it’s own special panache, attended by numerous Nobel Laureates who gathered to honor and celebrate the industry’s best. These gala photos paint a picture of an industry star-studded night.